Substance
ADALIMUMAB
Global reference: every product and company linked to this substance.
- cas: 331731-18-1
- ncit: C65216
- rxnorm: 327361
- unii: FYS6T7F842
ADALIMUMAB (GENETICAL RECOMBINATION) [JAN] · adalimumab [INN] · ADALIMUMAB [JAN] · ADALIMUMAB [USAN] · Adalimumab [WHO-DD] · D2E7 · LU-200134 · LU200134
Revenue by product (2)
| Company | Product | Latest period | Revenue |
|---|---|---|---|
| ABBVIE INC. COMMON STOCK | HUMIRA | Q2 2026 | $756.0M |
| ABBVIE INC. COMMON STOCK | HUMIRA | Q2 2026 | $756.0M |
A figure belongs to the product it was reported for. It is never summed across companies or across a company's products, so one substance in three products shows three figures.
Products containing this substance (2)
- HUMIRA · ABBVIE INC. COMMON STOCK
- HUMIRA · ABBVIE INC. COMMON STOCK